This capability is particularly valuable in MM as a highly heterogeneous disease composed of various molecular subgroups, each characterized by an assortment of genomic alterations with evolving treatment landscapes29,30, including therapies targeting BCMA. Here, TNFRSF17 is linked to Miyoshi myopathy.